The long-term outcomes and costs of diabetes mellitus among renal transplant recipients: Tacrolimus versus cyclosporine

Robert S. Woodward, Marc C. Flore, Gerardo Machnicki, Daniel Brennan

Research output: Contribution to journalArticle

Abstract

Anti-rejection regimens for renal transplants have changed dramatically during the past 20 years, but there are few long-term studies relating cost, mortality, or graft failure simultaneously to disease-pharmacotherapy couplets. We analyzed US Renal Data System data on a matched-pair cohort of first, single organ kidney transplants from 1998 through 2002 over up to 5 years following transplantation for patients on tacrolimus or low-dose cyclosporine, stratifying by whether the recipient had pre-existing or new onset diabetes. Kaplan-Meier survival curves show mortality and survival differences associated with diabetes, but no additional incremental effects of immune suppression regimen. Significant cost increases are reported for patients receiving tacrolimus above and beyond the extra costs associated with diabetes.

Original languageEnglish (US)
Pages (from-to)443-449
Number of pages7
JournalValue in Health
Volume14
Issue number4
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

Tacrolimus
Cyclosporine
Diabetes Mellitus
Transplants
Kidney
Costs and Cost Analysis
Mortality
Kaplan-Meier Estimate
Information Systems
Transplantation
Drug Therapy
Survival
Transplant Recipients

Keywords

  • Diabetes
  • Long-term costs
  • Long-term effects
  • Pharmacoeconomics
  • Renal transplantation

ASJC Scopus subject areas

  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

The long-term outcomes and costs of diabetes mellitus among renal transplant recipients : Tacrolimus versus cyclosporine. / Woodward, Robert S.; Flore, Marc C.; Machnicki, Gerardo; Brennan, Daniel.

In: Value in Health, Vol. 14, No. 4, 01.01.2011, p. 443-449.

Research output: Contribution to journalArticle

Woodward, Robert S. ; Flore, Marc C. ; Machnicki, Gerardo ; Brennan, Daniel. / The long-term outcomes and costs of diabetes mellitus among renal transplant recipients : Tacrolimus versus cyclosporine. In: Value in Health. 2011 ; Vol. 14, No. 4. pp. 443-449.
@article{58f576c3a1804c6ea5a1a8550b49c58a,
title = "The long-term outcomes and costs of diabetes mellitus among renal transplant recipients: Tacrolimus versus cyclosporine",
abstract = "Anti-rejection regimens for renal transplants have changed dramatically during the past 20 years, but there are few long-term studies relating cost, mortality, or graft failure simultaneously to disease-pharmacotherapy couplets. We analyzed US Renal Data System data on a matched-pair cohort of first, single organ kidney transplants from 1998 through 2002 over up to 5 years following transplantation for patients on tacrolimus or low-dose cyclosporine, stratifying by whether the recipient had pre-existing or new onset diabetes. Kaplan-Meier survival curves show mortality and survival differences associated with diabetes, but no additional incremental effects of immune suppression regimen. Significant cost increases are reported for patients receiving tacrolimus above and beyond the extra costs associated with diabetes.",
keywords = "Diabetes, Long-term costs, Long-term effects, Pharmacoeconomics, Renal transplantation",
author = "Woodward, {Robert S.} and Flore, {Marc C.} and Gerardo Machnicki and Daniel Brennan",
year = "2011",
month = "1",
day = "1",
doi = "10.1016/j.jval.2010.10.030",
language = "English (US)",
volume = "14",
pages = "443--449",
journal = "Value in Health",
issn = "1098-3015",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - The long-term outcomes and costs of diabetes mellitus among renal transplant recipients

T2 - Tacrolimus versus cyclosporine

AU - Woodward, Robert S.

AU - Flore, Marc C.

AU - Machnicki, Gerardo

AU - Brennan, Daniel

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Anti-rejection regimens for renal transplants have changed dramatically during the past 20 years, but there are few long-term studies relating cost, mortality, or graft failure simultaneously to disease-pharmacotherapy couplets. We analyzed US Renal Data System data on a matched-pair cohort of first, single organ kidney transplants from 1998 through 2002 over up to 5 years following transplantation for patients on tacrolimus or low-dose cyclosporine, stratifying by whether the recipient had pre-existing or new onset diabetes. Kaplan-Meier survival curves show mortality and survival differences associated with diabetes, but no additional incremental effects of immune suppression regimen. Significant cost increases are reported for patients receiving tacrolimus above and beyond the extra costs associated with diabetes.

AB - Anti-rejection regimens for renal transplants have changed dramatically during the past 20 years, but there are few long-term studies relating cost, mortality, or graft failure simultaneously to disease-pharmacotherapy couplets. We analyzed US Renal Data System data on a matched-pair cohort of first, single organ kidney transplants from 1998 through 2002 over up to 5 years following transplantation for patients on tacrolimus or low-dose cyclosporine, stratifying by whether the recipient had pre-existing or new onset diabetes. Kaplan-Meier survival curves show mortality and survival differences associated with diabetes, but no additional incremental effects of immune suppression regimen. Significant cost increases are reported for patients receiving tacrolimus above and beyond the extra costs associated with diabetes.

KW - Diabetes

KW - Long-term costs

KW - Long-term effects

KW - Pharmacoeconomics

KW - Renal transplantation

UR - http://www.scopus.com/inward/record.url?scp=79959949311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959949311&partnerID=8YFLogxK

U2 - 10.1016/j.jval.2010.10.030

DO - 10.1016/j.jval.2010.10.030

M3 - Article

C2 - 21315636

AN - SCOPUS:79959949311

VL - 14

SP - 443

EP - 449

JO - Value in Health

JF - Value in Health

SN - 1098-3015

IS - 4

ER -